The Task Force for Global Health

Legal name: Global Health Solutions Inc

Nonprofit profile at a glance

EIN
203674498
IRS 990 coverage
2009–2024
Official website data refreshed
Sep 2026
Forms available
Form 990 2024
Location
Decatur, GA, USA
Phone
404-371-0466
Rating
63
Verdict
SUPPORTED
Rating confidence
Moderate
Sector
Single Organization Support

Official website

Reported finances

Revenue
$772,045,614
Expenses
$772,045,614
Assets
$0
Liabilities
$0

Source: IRS Form 990. Selected filing: tax year 2024. Amounts in USD.

Leadership & pay

5 people listed

Highest reported compensation

  • Patrick O'Carroll (Chairman): $397,023 total reported compensation
  • Mark McKinlay (Officer): $245,812 total reported compensation
  • Ellen Wild (Treasurer): $237,534 total reported compensation

Source: IRS Form 990. Selected filing: tax year 2024. Names and roles reflect this filing, not necessarily current officeholders.

Overview

Mission

To address the world's most serious and pressing threats to global health and strengthen the systems that protect and promote health.

What it reported doing in 2024

Mectizan Donation Program In 2025, 349.1 million treatments were approved for mass drug administration (MDA) for onchocerciasis and lymphatic filariasis (LF) elimination in 36 countries and territories. The breakdown of treatments approved is as follows: 1) 240.9 million for onchocerciasis only including 30.6 million treatments approved to implement a second round of treatment in 8 countries (Brazil, Burkina Faso, DRC, Ethiopia, Malawi, Togo, Uganda and Venezuela). 2) 29.9 million for onchocerciasis & LF co-endemic communities. 3) 78.3 million for LF only, of which 51.4 million were approved for 11 countries and territories implementing triple therapy with ivermectin, DEC, and albendazole (IDA). The number of treatments approved in 2025 decreased compared with previous years. This decline is not only attributable to the downscaling of the LF programme, but also to the decision to implement only a single treatment round for onchocerciasis instead of two in Ghana, Tanzania, and Togo, following USAID-NTD funding cuts and a missed campaign in Mozambique and Angola. 2025, total shipments were down to 737.6 million tablets. This decrease was driven not only by the large number of tablets remaining in inventory after the 2024 annual mass drug administrations (MDAs) in countries (138.4 million tablets), but also by the deferral to 2026 of 179.7 million tablets originally scheduled for shipment in 2025 due to operational challenges in Nigeria, the Democratic Republic of the Congo, Mali, Sudan, and the Philippines By the end of 2025, cumulative shipments of Mectizan 3 mg tablets reached 14.66 billion, representing 5.23 billion treatments since the programme began in 1987. The milestone of 5 billion treatments was celebrated throughout the year.

Operating model

Revenue model
Donor-supported. 100% of the money available for current operations came from contributions and gifts.
Distribution model
Grant intermediary. The nonprofit sent 100% of its reported program spending out as grants.
  • Includes noncash contributions: Reported contributions include donated property or goods.

The verdict

SUPPORTED - A large share of available resources goes toward mission work and the filed numbers largely add up. A relatively small share of voting board members are independent and few specific pay-setting methods are documented in the filing; unanswered boxes are not proof of absence.

Rating breakdown

  • Financial Efficiency: 89
  • Transparency & Controls: 64
  • Accountability: 37
  • Sustainability: 14
  • Growth: 0

Detailed rating inputs

Financial Efficiency

  • Mission deployment rate: 100%; rating input score 100
  • Program expense ratio: 100%; rating input score 100
  • Fundraising efficiency: Limited

Transparency & Controls

  • Consistency checks: 100%; rating input score 100; 68th percentile among comparable filings
  • Pay-setting controls: 0 of 6 controls in place; rating input score 0
    • Compensation committee: Missing
    • Independent consultant: Missing
    • Other Form 990s reviewed: Missing
    • Written employment contract: Missing
    • Compensation survey or study: Missing
    • Board or committee approval: Missing
  • Foreign activity oversight: 2 of 8 controls in place; rating input score 25
    • Claims monitoring procedures: Pass
    • Requires narrative reports: Fail
    • Conducts field audits: Fail
    • May suspend future funding: Fail
    • Requires financial reports: Fail
    • Conducts site visits: Pass
    • Requires grant agreements: Fail
    • May require repayment: Fail
  • Grant itemization coverage: 100%; rating input score 100; 54th percentile among comparable filings
  • Major donor itemization: Yes; rating input score 100
  • Related-party transparency: Limited

Accountability

  • Independent voting board: 0%; rating input score 0; 4th percentile among comparable filings
  • Governance controls: 7 of 9 controls in place; rating input score 88
    • Conflict-of-interest policy: Pass
    • Whistleblower policy: Pass
    • Document-retention policy: Pass
    • CEO compensation review process: Limited
    • Other executive compensation review process: Fail
    • Form 990 shared with the board: Pass
    • Board meeting minutes documented: Pass
    • Audit committee oversight: Pass
    • Independent financial-statement audit: Pass

Sustainability

  • Operating margin: 0%; rating input score 29; 29th percentile among comparable filings
  • Total-asset coverage ratio: 0; rating input score 0; 0th percentile among comparable filings
  • Liabilities to assets ratio: Limited
  • Officer compensation ratio: Limited

Growth

  • Program expense growth: -12.4% per year; rating input score 0; 1st percentile among comparable filings
  • Revenue growth: -4.5% per year; rating input score 0; 1st percentile among comparable filings
  • Asset growth: -23.5% per year; rating input score 0; 0th percentile among comparable filings

Details

  • What they do: 12 programs and campaigns described on the official site · 1 operating location identified
  • Where the money goes: 100% of revenue deployed · 100% of spending went to programs
  • Governance: 0 of 4 board members independent · 7 of 9 filing controls reported
  • Programs: 2 filed program accomplishments · $772M in reported program spending
  • Leadership: top reported pay $397K · 5 people listed · 0 of 6 pay-setting controls reported
  • Consistency: 43 of 43 current checks pass
  • Schedules: 7 filed schedules · includes major donors, foreign activity, and executive pay
  • Filing history: 16 filing years from 2009 to 2024
  • Contacts: How to reach this organization
  • Related organizations: 1 filed related-organization link
  • Grant readiness: Federal tax and exclusion status, award history, and grant-maker relationships.
  • People: Everyone the filings name, and which of them the filings identify by more than a name.

Key Signals

Signals prioritize questions for review. They are not findings of misconduct.

  • High — Accountability: Independent voting board scored 0/100.
  • High — Transparency & Controls: Pay-setting controls scored 0/100.
  • High — Transparency & Controls: Foreign activity oversight: 6 of 8 not reported.
  • High — Sustainability: Operating margin scored 29/100.
  • High — Growth: Program expense growth scored 0/100.
  • High — Growth: Revenue growth scored 0/100.
  • High — Sustainability: Total-asset coverage ratio scored 0/100.
  • Review — Accountability: Governance controls: Other executive compensation review process not reported.
  • High — Growth: Asset growth scored 0/100.